Panofen (Venlafaxine)

Venlafaxine, the active ingredient in Panofen, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as a strength/form for oral use. It is indicated for the treatment of major depressive disorder and other mood disorders in adults.

GNH USA supplies Panofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Venlafaxine is an SNRI that modulates neurotransmitter activity in mood‑related pathways. - Major depressive disorder: alleviates depressive symptoms and improves functional outcomes. - Generalized anxiety disorder: reduces anxiety levels and associated physical symptoms. - Social anxiety disorder: diminishes social fear and avoidance behaviors. - Panic disorder: lowers frequency and severity of panic attacks.

Venlafaxine may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dry mouth: reduced salivation. - Insomnia: difficulty falling or staying asleep. - Dizziness: sensation of light‑headedness. - Sweating: increased perspiration, especially at night. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Hypertensive crisis: sudden, severe increase in blood pressure. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Liver injury: abnormal liver function tests or hepatitis. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Venlafaxine, clinicians should consider several safety aspects. - Monitor blood pressure: check regularly, especially at higher doses. - Assess mental health: watch for worsening depression or emergence of suicidal thoughts. - Evaluate liver function: periodic testing recommended for patients with hepatic impairment. - Use caution in pregnancy: weigh benefits against potential risks to the fetus. - Avoid abrupt discontinuation: taper dose to minimise withdrawal symptoms. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Venrafine interacts with several drug classes that may require dose adjustments or monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Triplet treatments of serotonergic agents including SSRIs, SNRIs and TCAs. - Linezolid: potential for hypertensive crisis.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase bleeding risk. - Warfarin: possible alteration of INR values. - Carbamazepine: may reduce venous plasma levels. - Alcohol: can enhance central nervous system depression.